Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / FDA     showing 1–3 of 3   RSS


for: Saturday, May 16, 2026



FDA clears 1st AI sepsis monitoring tool

Giles Bruce / beckershospitalreview - A tool from tech company Bayesian Health has become the first continuous AI sepsis monitor to gain FDA approval. The solution monitors hospital patients to detect deterioration and flag sepsis early on. The application was developed at Baltimore-based Joh…

AI Summary: Regulators have cleared the first AI‑driven sepsis early‑warning system for clinical deployment, enabling hospitals to use algorithmic alerts to identify patients at risk of deterioration earlier. The clearance opens the door for broader adoption of AI in acute care while renewing debates about clinical oversight, false alarms and integration into existing workflows.

#healthcare #publichealth #fda #digitalhealth #medicaldevices #hospitaloperations #infectiousdisease #healthit #diagnostics

15 days / nature

19 days / medicalxpress


Back to Top / Saturday, May 16, 2026, 1:21 am / permalink 23878 / 7 stories in 15 days /

BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...

AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.

#pharmaceuticals #drugpricing #biotech #drugdevelopment #fda #oncology #healthcarefinance #cancerresearch #clinicaltrials

Back to Top / Saturday, May 16, 2026, 12:21 am / permalink 23871 / 2 stories in 15 days /

Positive VOLGA Phase III Results for Imfinzi Plus Neoadjuvant EV in MIBC

oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]

AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.


Clinician reactions, biology and resistance concerns

13 days / medicalxpress

14 days / oncodaily

15 days / oncodaily

17 days / oncodaily


Global GU oncology meetings and community coverage

11 days / oncodaily

13 days / oncodaily

15 days / oncodaily


VOLGA Phase III readout and regulatory landscape

15 days / oncodaily

16 days / oncodaily


All Other Stories

8 days / oncodaily

9 days / oncodaily

9 days / oncodaily

9 days / oncodaily

10 days / medicalxpress

10 days / oncodaily

10 days / oncodaily

10 days / esmo

11 days / oncodaily

13 days / oncodaily



Back to Top


FDA Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare Finance, Telemedicine, Avian Influenza, Public Health and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.